![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » DRUG CANDIDATE SHOWS POTENT ANTIVIRAL ACTIVITY IN HIV-INFECTED PATIENTS
DRUG CANDIDATE SHOWS POTENT ANTIVIRAL ACTIVITY IN HIV-INFECTED PATIENTS
Panacos Pharmaceuticals announced the successful completion of a Phase IIa clinical study of its lead HIV drug candidate, PA-457, and provided preliminary analysis of the results. The study met its primary endpoint by demonstrating a statistically significant reduction in the level of HIV in the blood, known as viral load, compared to placebo.
In this randomized, double-blind study, performed at leading academic centers in the U.S., PA-457 at one of four doses (25, 50, 100 or 200 mg; six patients per group) or placebo (eight patients), was administered orally once daily for 10 days to HIV-infected subjects not on other antiretroviral therapy. The primary endpoint was viral load reduction on Day 11. Other endpoints included safety, tolerability and pharmacokinetics of the drug.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct